Are scores useful in advanced heart failure?

Expert Review of Cardiovascular Therapy

Volumn 7, Issue 8, 2009, Pages 985-997

  Goldraich, Livia ^a   Beck da Silva, Luis ^a   Clausell, Nadine ^a  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Advanced heart failure; Prognosis; Risk assessment

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NATRIURETIC FACTOR; SPIRONOLACTONE; VALSARTAN;

AREA UNDER THE CURVE; ARTIFICIAL HEART PACEMAKER; CAREGIVER; CLINICAL TRIAL; DECISION MAKING; DIASTOLIC BLOOD PRESSURE; GENE FREQUENCY; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART TRANSPLANTATION; HUMAN; MORBIDITY; MORTALITY; OXYGEN CONSUMPTION; PROGNOSIS; QRS COMPLEX; QUALITY OF LIFE; RACE DIFFERENCE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SURVIVAL RATE; SYSTOLIC BLOOD PRESSURE; UREA NITROGEN BLOOD LEVEL; BIOLOGICAL MODEL; HOSPITALIZATION; METHODOLOGY; REGRESSION ANALYSIS;

CLINICAL TRIALS AS TOPIC; HEART FAILURE; HUMANS; MODELS, BIOLOGICAL; PROGNOSIS; REGRESSION ANALYSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX;

EID: 70350437795     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.09.68     Document Type: Review

References (64)

1. Rosamond W, Flegal K, Furie K et al. Heart Disease and Stroke Statistics - 2008 Update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117(4), E25-E146 (2008).
2. Bleumink GS, Knetsch AM, Sturkenboom MCJM et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure: The Rotterdam Study. Eur. Heart J. 25(18), 1614-1619 (2004).
3. Krum H, Gilbert RE. Demographics and concomitant disorders in heart failure. Lancet 362, 147-158 (2003). (Pubitemid 36831029)
4. Solomon SD, Dobson J, Pocock S et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation 116(13), 1482-1487 (2007). (Pubitemid 47480639)
5. Pocock SJ, Wang D, Pfeffer MA et al. Predictors of mortality and morbidity in patients with chronic heart failure. Eur. Heart J. 27(1), 65-75 (2006). (Pubitemid 41785934)
6. Setoguchi S, Stevenson LW, Schneeweiss S. Repeated hospitalizations predict mortality in the community population with heart failure. Am. Heart J. 154(2), 260-266 (2007). (Pubitemid 47079017)
7. Aaronson KD, Schwartz JS, Chen T-M, Wong K-L, Goin JE, Mancini DM. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation 95(12), 2660-2667 (1997).
8. Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA 290(19), 2581-2587 (2003). (Pubitemid 37443288)
9. Fonarow GC, Adams KF Jr, Abraham WT et al. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA 293(5), 572-580 (2005).
10. Levy WC, Mozaffarian D, Linker DT et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation 113(11), 1424-1433 (2006). (Pubitemid 43739439)
11. Rohde LE, Goldraich L, Polanczyk CA et al. A simple clinically based predictive rule for heart failure in-hospital mortality. J. Card. Fail. 12(8), 587-593 (2006). (Pubitemid 44540258)
12. O'Connor CM, Abraham WT, Albert NM et al. Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am. Heart J. 156(4), 662-673 (2008).
13. Abraham WT, Fonarow GC, Albert NM et al. Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF). J. Am. Coll. Cardiol. 52(5), 347-356 (2008).
14. Adams KF, Zannad F. Clinical definition and epidemiology of advanced heart failure. Am. Heart J. 135(6), S204-S215 (1998). (Pubitemid 28350123)
15. ESCAPE Study Coordinators. Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness: the ESCAPE trial. JAMA 294(13), 1625-1633 (2005).
16. Mehra MR, Kobashigawa J, Starling RC et al. Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates - 2006. J. Heart Lung Transplant. 25(9), 1024-1042 (2006). (Pubitemid 44311532)
17. Metra M, Ponikowski P, Dickstein K et al. Advanced chronic heart failure: a position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. Eur. J. Heart Fail. 9(6), 684-694 (2007). (Pubitemid 46705572)
18. Peterson LR, Schechtman KB, Ewald GA et al. The effect of β-adrenergic blockers on the prognostic value of peak exercise oxygen uptake in patients with heart failure. J. Heart Lung Transplant. 22(1), 70-77 (2003).
19. Lund LH, Aaronson KD, Mancini DM. Predicting survival in ambulatory patients with severe heart failure on β-blocker therapy. Am. J. Cardiol. 92(11), 1350-1354 (2003).
20. Koelling TM, Joseph S, Aaronson KD. Heart failure survival score continues to predict clinical outcomes in patients with heart failure receiving β-blockers. J. Heart Lung Transplant. 23(12), 1414-1422 (2004). (Pubitemid 40018165)
21. Zugck C, Haunstetter A, Kruger C et al. Impact of β-blocker treatment on the prognostic value of currently used risk predictors in congestive heart failure. J. Am. Coll. Cardiol. 39(10), 1615-1622 (2002). (Pubitemid 34494284)
22. Arena R, Myers J, Williams MA et al. Assessment of functional capacity in clinical and research setting. A Scientific Statement from the American Heart Association Committee on Exercise, Rehabilitation, and Prevention of the Council on Clinical Cardiology and the Council on Cardiovascular Nursing. Circulation 116(3), 329-343 (2007). (Pubitemid 47196569)
23. Pfeffer M, Swedberg K, Granger CB et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362, 759-766 (2003). (Pubitemid 37093915)
24. Mauro F, Nadia A, Cristina C et al. Prognostic value of plasma brain natriuretic peptide, urea nitrogen, and creatinine in outpatients >70 years of age with heart failure. Am. J. Cardiol. 96(5), 705-709 (2005).
25. Forman DE, Butler J, Wang Y et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J. Am. Coll. Cardiol. 42, 61-67 (2004). (Pubitemid 38045917)
26. Mozaffarian D, Anker SD, Anand I et al. Prediction of mode of death in heart failure: The Seattle Heart Failure Model. Circulation 116(4), 392-398 (2007). (Pubitemid 47196544)
27. May HT, Horne BD, Levy WC et al. Validation of the Seattle Heart Failure Model in a community-based heart failure population and enhancement by adding B-type natriuretic peptide. Am. J. Cardiol. 100(4), 697-700 (2007).
28. Philbin EF, DiSalvo TG. Prediction of hospital readmission for heart failure: development of a simple risk score based on administrative data. J. Am. Coll. Cardiol. 33(6), 1560-1566 (1999).
29. Fonarow G. Epidemiology and risk stratification in acute heart failure. Am. Heart J. 155(2), 200-207 (2008).
30. Felker GM, Adams KF, Konstam MA, O'Connor CM, Gheorghiade M. The problem of decompensated heart failure: nomenclature, classification, and risk stratification. Am. Heart J. 145(2), S18-S25 (2003).
31. Braunwald E. Biomarkers in heart failure. N. Engl. J. Med. 358(20), 2148-2159 (2008).
32. Dries DL, Exner DV, Gersh BJ, Cooper HA, Carson PE, Domanski MJ. Racial differences in the outcome of left ventricular dysfunction. N. Engl. J. Med. 340(8), 609-616 (1999).
33. Yancy C. Heart failure in African Americans: a cardiovascular enigma. J. Card. Fail. 6(3), 183-186 (2000). (Pubitemid 30683543)
34. Yancy C. Does race matter in heart failure? Am. Heart J. 146(2), 203-206 (2003). (Pubitemid 36951759)
35. Gottlieb SS. Prognostic indicators: useful for clinical care? J. Am. Coll. Cardiol. 53(4), 343-344 (2009).
36. 1-adrenergic receptor motif alters cardiac function and β-blocker response in human heart failure. Proc. Natl Acad. Sci. USA 103(30), 11288-11293 (2006).
37. Eichhorn EJ, Domanski MJ, Krause-Steinrauf H, Bristow MR, Lavori PW; BEST Investigators. A trial of the b-blocker bucindolol in patients with advanced chronic heart failure. N. Engl. J. Med. 344(22), 1659-1667 (2001).
38. Kalogeropoulos AP, Georgiopoulou VV, Giamouzis G et al. Utility of the Seattle Heart Failure Model in patients with advanced heart failure. J. Am. Coll. Cardiol. 53(4), 334-342 (2009).
39. Myers J, Gullestad L, Vagelos R et al. Cardiopulmonary exercise testing and prognosis in severe heart failure: 14 ml/kg/min revisited. Am. Heart J. (139), 78-84 (2000). (Pubitemid 30043628)
40. Pohwani AL, Murali S, Mathier MM et al. Impact of β-blocker therapy on functional capacity criteria for heart transplant listing. J. Heart Lung Transplant. 22(1), 78-86 (2003). (Pubitemid 36071420)
41. Butler J, Khadim G, Paul K et al. Selection of patients for heart transplantation in the current era of heart failure therapy. J. Am. Coll. Cardiol. 43(5), 787-793 (2004). (Pubitemid 38296477)
42. Nohria A, Tsang SW, Fang JC et al. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J. Am. Coll. Cardiol. 41(10), 1797 - 1804 (2003).
43. Rohde LE, Beck da Silva L, Goldraich L et al. Reliability and prognostic value of traditional signs and symptoms in outpatients with congestive heart failure. Can. J. Cardiol. 20(7), 697-702 (2004). (Pubitemid 38968019)
44. Troughton RW, Frampton C, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355, 1126-1130 (2000). (Pubitemid 30172933)
45. Rohde LE, Palombini DV, Polanczyk CA, Goldraich L, Clausell N. A hemodynamically oriented echocardiography-based strategy in the treatment of congestive heart failure. J. Card. Fail. 13(8), 618-625 (2007). (Pubitemid 47513541)
46. Stevenson LW, Tillisch JH, Hamilton M et al. Importance of hemodynamic response to therapy in predicting survival with ejection fraction less than or equal to 20% secondary to ischemic or nonischemic dilated cardiomyopathy. Am. J. Cardiol. 66(19), 1348-1354 (1990).
47. Beck da Silva L, Mielniczuk L, Laberge M et al. Persistent orthopnea and the prognosis of patients in the heart failure clinic. Congest. Heart Fail. 10, 177-180 (2004).
48. Lund L, Aaronson K, Mancini D. Validation of peak exercise oxygen consumption and the heart failure survival score for serial risk stratification in advanced heart failure. Am. J. Cardiol. 95, 734-741 (2005). (Pubitemid 40332651)
49. Allen LA, Yager JE, Funk MJ et al. Discordance between patient-predicted and model-predicted life expectancy among ambulatory patients with heart failure. JAMA 299(21), 2533-2542 (2008).
50. Yancy C. Predicting life expectancy in heart failure. JAMA 299, 2566-2567 (2008). (Pubitemid 351787215)
51. Stevenson LW, Hellcamp AS, Leier CV et al. Changing preferences for survival after hospitalization with advanced heart failure. J. Am. Coll. Cardiol. 52(21), 1702-1708 (2008).
52. Yamokoski LM, Hasselblad V, Moser DM et al. Prediction of rehospitalization and death in severe heart failure by physicians and nurses of the ESCAPE trial. J. Card. Fail. 13(1), 8-13 (2007). (Pubitemid 46330838)
53. Guyatt GH, Haynes RB, Jaeschke RZ et al. Users' guides to the medical literature: XXV. Evidence-based medicine: principles for applying the users' guides to patient care. JAMA 284(10), 1290-1296 (2000).
54. Stevenson LW. Design of therapy for advanced heart failure. Eur. J. Heart Fail. 7, 323-331 (2005).
55. Stevenson LW. Clinical use of inotropic therapy for heart failure: looking backward or forward? part i: inotropic infusions during hospitalization. Circulation 108, 367-372 (2003).
56. O'Connor CM, Gattis WA, Uretsky BF et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure insights from the Flolan International Randomized Survival Trial (FIRST). Am. Heart J. 138, 78-86 (1999).
57. Jong P, Yusuf S, Rousseau MF, Ahn SA, Bangdiwala SI. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet 361(9372), 1843-1848 (2003).
58. Packer M, Fowler MB, Roecker EB et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study. Circulation 106(17), 2194-2199 (2002). (Pubitemid 35222212)
59. Lewis EF, Johnson PA, Johnson W, Collins C, Griffin L, Stevenson LW. Preferences for quality of life or survival expressed by patients with heart failure. J. Heart Lung Transplant. 20(9), 1016-1024 (2001). (Pubitemid 32824149)
60. Packer M, O'Connor CM, Ghali JK et al. Effect of amlodipine on morbidity and mortality in severe and chronic heart failure. New Engl. J. Med. 335, 1107-1114 (1996). (Pubitemid 26330964)
61. The Seattle Heart Failure Model. University of Washington, DC, USA www.seattleheartfailuremodel.org
62. Enhanced Feedback for Effective Cardiac Treatment (EFFECT) study. Canadian Cardiovascular Outcomes Research Team www.ccort.ca/CHFriskmodel.asp
63. Acute Decompensated Heart Failure National Registry www.adhereregistry. com
64. Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure www.optimize-hf.or